ARMP logo

ARMP
Armata Pharmaceuticals Inc

8,230
Mkt Cap
$375.12M
Volume
25,916.00
52W High
$16.34
52W Low
$0.8981
PE Ratio
-2.21
ARMP Fundamentals
Price
$10.56
Prev Close
$10.24
Open
$10.25
50D MA
$8.92
Beta
0.53
Avg. Volume
31,905.13
EPS (Annual)
-$4.80
P/B
-1.76
Rev/Employee
$80,393.44
$506.91
Loading...
Loading...
News
all
press releases
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results PR Newswire LOS ANGELES...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025...
PR Newswire·14d ago
News Placeholder
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for...
PR Newswire·1mo ago
News Placeholder
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus Armata Pharmaceuticals...
PR Newswire·3mo ago
News Placeholder
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Armata Pharmaceuticals (ARMP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·5mo ago
News Placeholder
Armata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In
Stocktwits·5mo ago
<
1
2
...
>

Latest ARMP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.